Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.74 |
| ▸ | POLB | P06746 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | MEN1 | O00255 | 1/20 | 0.64 |
| ▸ | MITF | O75030 | 1/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | THRB | P10828 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23130338 | 0.82 | POLB (1.00) | HPGDPOLBALDH1A1RAB9AMEN1 | |
| SCHEMBL24133895 | 0.78 | HPGD (0.75) | HPGDPOLBALDH1A1RAB9ATSHR | |
| SCHEMBL2985973 | 0.76 | ALDH1A1 (0.49) | HPGDALDH1A1RAB9AMEN1KMT2A | |
| SCHEMBL11272203 | 0.76 | ALDH1A1 (0.60) | HPGDPOLBALDH1A1RAB9AMEN1 | |
| SCHEMBL12007407 | 0.75 | NPC1 (0.73) | HPGDPOLBALDH1A1MEN1KMT2A | |
| SCHEMBL18719809 | 0.74 | KMT2A (0.59) | HPGDPOLBALDH1A1RAB9AMEN1 | |
| SCHEMBL18719848 | 0.74 | ALDH1A1 (0.63) | HPGDPOLBALDH1A1RAB9AMEN1 | |
| SCHEMBL1015064 | 0.73 | HPGD (0.56) | HPGDPOLBALDH1A1RAB9AMEN1 | |
| SCHEMBL12196171 | 0.72 | EPHX1 (1.00) | HPGDPOLBALDH1A1RAB9AMEN1 | |
| SCHEMBL19134217 | 0.71 | ATF4 (0.86) | HPGDPOLBALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | BIOMARIN PHARMACEUTICAL INC. | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120100609-A1 | N-LINKED GLYCAN BIOSYNTHESIS MODULATORS | ENGASE, GALNT1, GALNT13 | HPGD 989/4885POLB 2362/4885ALDH1A1 2125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.